Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: A retrospective cost-effectiveness analysis
Huseyin Naci, Gregory De Lissovoy, Christopher Hollenbeak, Brian Custer, Axel Hofmann, William McClellan, Matthew Gitlin
Dive into the research topics of 'Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: A retrospective cost-effectiveness analysis'. Together they form a unique fingerprint.